IMNN (Imunon) Short Interest


IMNN Imunon Inc IMNN
26 GF Score
Price $1.73
! 2 Warning Signs
View Full Analysis

What is Imunon Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

IMNN vs PMCB, CURX, LABT: Short Interest Comparison

For the Biotechnology subindustry, Imunon's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imunon Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Short Interest distribution charts can be found below:

* The bar in red indicates where Imunon's Short Interest falls into.


IMNN
26GF Score
Imunon Inc IMNN
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imunon Business Description

Other Exchanges CBO0:Germany
Address 997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
26GF Score

Get the complete analysis for IMNN

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.73
Price